Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-001 in TMB-H Solid Tumors
NCT06365840Phase 2Recruiting
- Sponsor
- ImmuneOncia Therapeutics, Inc.
- Start
- Jan 2025
- Primary completion
- Jun 2027
- Modality
- CAR-T Cells, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of IMC-001 in solid tumor, sponsored by ImmuneOncia Therapeutics, Inc.. Started Jan 2025; status: recruiting.
02
Drugs
IMC-001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06365840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06365840.